Li Peng, PhDChief Scientific Officer at Palleon PharmaceuticalsSpeaker
Profile
Li Peng is CSO of Palleon Pharmaceuticals, a pioneer in glycan-targeted therapies for cancer and inflammatory diseases. With 20+ years of industry experience, Li has led the invention of Palleon’s EAGLE, CONVERGENCE, and HYDRA platform technologies and oversees Palleon's research and early development. Prior to joining Palleon, Li spent ten years at MedImmune/AstraZeneca in roles of increasing responsibility. She has authored approximately 30 scientific publications and is an inventor on approximately 20 patents and patent applications.
Agenda Sessions
Targeted Tumor Desialylation by a Sialidase-Armed Anti-B7-H3 Nanobody Enhances Antitumor Immunity on core
, 11:30amView Session
